Table 3 Analyses of the associations of sCD73 activity and progression-free survival
From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Univariate | Multivariate | |
|---|---|---|
HR (95% CI) P value | HR (95% CI) P value | |
Gender (M vs. F) | 1.64 (0.73–3.70) P = 0.23 | n.s. |
Age, years (≥ 62 vs. < 62) | 1.30 (0.59–2.89) P = 0.52 | n.s. |
BRAF status (mut vs. wt) | 0.72 (0.30–1.69) P = 0.45 | n.s. |
LDH, IU/L (≥ 480 vs. < 480) | 2.37 (1.04–5.39) P = 0.04 | n.s. |
Line of treatment (> 2 vs. 2) | 2.34 (1.02–5.34) P = 0.04 | n.s. |
Brain METS (yes vs. no) | 1.33 (0.53–3.36) P = 0.54 | n.s. |
Basal sCD73 activity (≥ 27.8 vs. < 27.8) | 4.24 (1.64–10.93) P = 0.003 | 4.24 (1.64–10.93) P = 0.003 |